Arpita Lakhotia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arpita Lakhotia has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Amira Al‐Uzri
Oregon Health and Science University, Portland, USA
2 shared publications - Chi Dang Hornik
Department of Pediatrics, Duke University School of Medicine, Durham, USA
2 shared publications - Daniel Gonzalez
Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, USA
2 shared publications - Jaydeep Sinha
Department of Pediatrics, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, USA
2 shared publications - Jia-Yuh Chen
The Emmes Company, LLC, Rockville, USA
2 shared publications - Kanecia O. Zimmerman
Department of Pediatrics, Duke University School of Medicine, Durham, USA
2 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in SSRN Electronic Journal
Polysomnographic Characteristics in Children with Spinal Muscular Atrophy Compared to Healthy Children: A Retrospective Analysis
Introduction: Children with spinal muscular atrophy (SMA) are at high risk for sleep-disordered breathing (SDB). This study compared polysomnogram (PSG) findings in children with SMA versus healthy controls and differences by functional status. Methods: In this single-center retrospective study, 17 children with confirmed SMA underwent an overnight PSG and were compared with 17 controls matched by age, sex, body mass index (BMI), and apnea–hypopnea index (AHI). Obstructive sleep apnea (OSA) severity was defined by obstructive AHI (OAHI): normal (<1/hr), mild (1–4.9), moderate (5–9.9), and severe (≥10). Results: Thirty-four PSGs were analyzed. Mean age was 4.0 (SMA) vs. 4.7 years (controls); 70.6% were female. OSA distribution was similar in both groups (47% none, 29% mild, 17% moderate, and 5% severe). Compared to controls, the SMA group had lower total sleep time (386.5 vs. 421.5 min, p=0.022), less N1 sleep (3.5 vs. 18.5 min, p=0.006), and reduced non-rapid eye movement (non-REM) sleep (255.3 vs. 333.2 min, p=0.004). Mean non-REM carbon dioxide (CO₂) was lower (39.5 vs. 42.3 mmHg, p=0.011), while mean heart rate (HR) was higher (100.8 vs. 87.1 bpm, p=0.017) in the SMA group. Central apnea (CA) time differed by functional status (non-sitters 3.8 seconds, sitters 2.9 seconds, and walkers 5.5 seconds; p=0.021). Periodic limb movement index (PLMI) was the highest in walkers (7.1 vs. 0.0 in other groups; p=0.02). Conclusion: Over half of the children with SMA exhibited SDB. Compared with AHI-matched controls, they showed reduced TST, lower non-REM CO₂, and PSG differences across functional statuses.
- 15 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPolysomnographic Characteristics in Children with Spinal Muscular Atrophy Compared to Healthy Children: A Retrospective Analysis
Introduction: Children with spinal muscular atrophy (SMA) are at high risk for sleep-disordered breathing (SDB). This study compared polysomnogram (PSG) findings in children with SMA versus healthy controls and differences by functional status. Methods: In this single-center retrospective study, 17 children with confirmed SMA underwent an overnight PSG and were compared with 17 controls matched by age, sex, body mass index (BMI), and apnea–hypopnea index (AHI). Obstructive sleep apnea (OSA) severity was defined by obstructive AHI (OAHI): normal (<1/hr), mild (1–4.9), moderate (5–9.9), and severe (≥10). Results: Thirty-four PSGs were analyzed. Mean age was 4.0 (SMA) vs. 4.7 years (controls); 70.6% were female. OSA distribution was similar in both groups (47% none, 29% mild, 17% moderate, and 5% severe). Compared to controls, the SMA group had lower total sleep time (386.5 vs. 421.5 min, p=0.022), less N1 sleep (3.5 vs. 18.5 min, p=0.006), and reduced non-rapid eye movement (non-REM) sleep (255.3 vs. 333.2 min, p=0.004). Mean non-REM carbon dioxide (CO₂) was lower (39.5 vs. 42.3 mmHg, p=0.011), while mean heart rate (HR) was higher (100.8 vs. 87.1 bpm, p=0.017) in the SMA group. Central apnea (CA) time differed by functional status (non-sitters 3.8 seconds, sitters 2.9 seconds, and walkers 5.5 seconds; p=0.021). Periodic limb movement index (PLMI) was the highest in walkers (7.1 vs. 0.0 in other groups; p=0.02). Conclusion: Over half of the children with SMA exhibited SDB. Compared with AHI-matched controls, they showed reduced TST, lower non-REM CO₂, and PSG differences across functional statuses.
- Open Access
- 6 January 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 345
Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity
- 6 January 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 345
Open AccessCorrection: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity
- Open Access
- 17 November 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 329-344
Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity
Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.
- 17 November 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 329-344
Open AccessPopulation Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity
Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.
- 11 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (3) , e213329
Teaching NeuroImage: “Broomstick-Like” Appearance of Intracranial Arteries in ACTA2 Leukovasculopathy
- 11 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (3) , e213329
Teaching NeuroImage: “Broomstick-Like” Appearance of Intracranial Arteries in ACTA2 Leukovasculopathy
- Open Access
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (4) , e200310
Spinal Muscular Atrophy Update in Best Practices
Spinal muscular atrophy (SMA) is an autosomal recessive progressive neurodegenerative primary motor neuron disorder caused by biallelic variants of the survival motor neuron 1 (SMN1) gene. The most recent SMA best practice recommendations were published in 2018 shortly after the approval of the first SMN-enhancing treatment. The availability of disease-modifying therapies for 5q SMA and implementation of SMA newborn screening (NBS) has led to urgency to update the SMA best practice recommendations for diagnosis and to reevaluate the current classification of SMA. In addition, the availability of disease-modifying therapies has opened the door to explore improved diagnosis of adult-onset SMA. A systematic literature review was conducted on SMA NBS. An SMA working group of American and European health care providers developed recommendations through a modified Delphi technique with serial surveys and virtual meeting feedback on SMA diagnosis to fill information gaps for topics with limited evidence. A community working group of an individual with SMA and caregivers provided insight and perspective on SMA diagnosis and support through a virtual meeting to guide recommendations. The health care provider working group achieved consensus that SMA NBS is essential to include in the updated best practice for SMA diagnosis (100%). Recommendations for the following are described: characterizing NBS-identified infants before treatment; minimum recommendations for starting or offering SMA NBS in a state or country; recommendations for activities and services to be provided by an SMA specialty care center accepting SMA NBS referrals; and recommendations for partnership with individuals with SMA and caregivers to support NBS-identified infants and their caregivers. Limited data are available to advance efficient diagnosis of adult-onset SMA. Updating best practice recommendations for SMA diagnosis to include SMA NBS implementation is essential to advancing care for individuals with SMA. In addition to testing, processes for the efficient management of positive newborn screen with access to knowledgeable and skilled health care providers and access to treatment options is critical to successful early diagnosis. Additional evidence is required to improve adult-onset SMA diagnosis.
- 1 August 2024
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 14 (4) , e200310
Open AccessSpinal Muscular Atrophy Update in Best Practices
Spinal muscular atrophy (SMA) is an autosomal recessive progressive neurodegenerative primary motor neuron disorder caused by biallelic variants of the survival motor neuron 1 (SMN1) gene. The most recent SMA best practice recommendations were published in 2018 shortly after the approval of the first SMN-enhancing treatment. The availability of disease-modifying therapies for 5q SMA and implementation of SMA newborn screening (NBS) has led to urgency to update the SMA best practice recommendations for diagnosis and to reevaluate the current classification of SMA. In addition, the availability of disease-modifying therapies has opened the door to explore improved diagnosis of adult-onset SMA. A systematic literature review was conducted on SMA NBS. An SMA working group of American and European health care providers developed recommendations through a modified Delphi technique with serial surveys and virtual meeting feedback on SMA diagnosis to fill information gaps for topics with limited evidence. A community working group of an individual with SMA and caregivers provided insight and perspective on SMA diagnosis and support through a virtual meeting to guide recommendations. The health care provider working group achieved consensus that SMA NBS is essential to include in the updated best practice for SMA diagnosis (100%). Recommendations for the following are described: characterizing NBS-identified infants before treatment; minimum recommendations for starting or offering SMA NBS in a state or country; recommendations for activities and services to be provided by an SMA specialty care center accepting SMA NBS referrals; and recommendations for partnership with individuals with SMA and caregivers to support NBS-identified infants and their caregivers. Limited data are available to advance efficient diagnosis of adult-onset SMA. Updating best practice recommendations for SMA diagnosis to include SMA NBS implementation is essential to advancing care for individuals with SMA. In addition to testing, processes for the efficient management of positive newborn screen with access to knowledgeable and skilled health care providers and access to treatment options is critical to successful early diagnosis. Additional evidence is required to improve adult-onset SMA diagnosis.
- Open Access
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (4)
Posterior circulation
- 1 July 2023
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 3 (4)
Open AccessPosterior circulation
- 13 October 2021
- Published by Wiley in Muscle & Nerve
- Vol. 65 (1) , E2-E3
Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient
- 13 October 2021
- Published by Wiley in Muscle & Nerve
- Vol. 65 (1) , E2-E3
Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient
- 1 January 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 114, 75-76
N-Methyl-d-Aspartate Receptor Encephalitis Associated With COVID-19 Infection in a Toddler
- 1 January 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 114, 75-76
N-Methyl-d-Aspartate Receptor Encephalitis Associated With COVID-19 Infection in a Toddler
- 17 May 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 74, 104-105
A Child With Progressive Leg Weakness
- 17 May 2017
- Published by Elsevier in Pediatric Neurology
- Vol. 74, 104-105
A Child With Progressive Leg Weakness
- 1 December 2016
- Published by Elsevier in Pediatric Neurology
- Vol. 65, 100-101
A Hidden Cause of Hemorrhage: Cavernous Venous Malformation
- 1 December 2016
- Published by Elsevier in Pediatric Neurology
- Vol. 65, 100-101
A Hidden Cause of Hemorrhage: Cavernous Venous Malformation